Belgium-headquartered Exothera, a leading provider of nucleic acids and viral vector development and manufacturing services, has launched its game-changing nucleic acids service offering, powered by the world’s first continuous-batch RNA production platform, Ntensify™. Developed by Exothera sister company Quantoom Biosciences, the Ntensify™ platform fast-tracks the production of higher quality and more cost-effective RNA therapeutics, delivering significant advantages at both small and large scale. It is also now available to biopharma companies in North America for the first time as Exothera expands its reach beyond Europe.
The National Institutes of Health (NIH), the US’s medical research agency, selected Exothera S.A., a full-service Contract Development and Manufacturing Organization (CDMO) specialized in gene therapy, vaccines, oncolytic viruses, and nucleic acid-based therapeutics, to develop the manufacturing process for NIH’s intranasal vaccine against SARS-CoV-2. As part of the Cooperative Research and Development Agreement, CRADA, they will be joined by researchers from Dartmouth Health’s Dartmouth Hitchcock Medical Center (DHMC) and Dartmouth’s Geisel School of Medicine with special expertise in mucosal immunity and the design and conduct of early phase clinical trials.
Meissa Vaccines Enters into cGMP Manufacturing Agreement for Pediatric RSV Vaccine Candidate for Phase 2 Clinical Trials
Exothera Nucleic Acids Strengthens Team with Industry Expert
Remedium Bio, a biotechnology company developing a lead candidate disease modifying treatment for Osteoarthritis (OA), and Exothera S.A., a full-service CDMO specialized in gene therapy, vaccines, and oncolytic viruses, entered a collaboration agreement to demonstrate the industrialization potential of Remedium’s AAV2-FGF18.
Exothera S.A., a full-service Contract Development and Manufacturing Organization (CDMO), has appointed Darren Leva as Chief Business Officer.
Valo Therapeutics selects Exothera to develop large-scale oncolytic Adenovirus manufacturing
Vaccizone, a vaccine development company focusing on innovative antigen delivery technology, selected the contract development and manufacturing organization (CDMO) Exothera S.A. to fast-track process development of its SARS?CoV?2 vaccine for European clinical trials.
Exothera SA today announced a collaboration with LogicBio® Therapeutics and Polyplus-transfection® SA. for the development of a highly scalable AAV...
ReiThera Srl, a biotech company dedicated to the technology development, GMP manufacturing and clinical translation of genetic vaccines and medicinal products for advanced therapies, and Exothera, a full-service contract development and manufacturing organization (CDMO), have entered into a collaboration agreement to develop a large-scale, low cost per dose manufacturing process for the production of ReiThera’s novel vaccines.